Acorda Therapeutics Return on Equity

Acorda Therapeutics (ACOR) currently reports a ROE of 141.8%. That is above the Healthcare sector average of -100.59%. Use the charts on this page to explore Acorda Therapeutics's ROE history and peer comparisons.

Acorda Therapeutics's ROE of 141.8% is higher than the Healthcare sector average of -100.59%. That is roughly 241.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Acorda Therapeutics's current 141.8% should be judged against Healthcare norms (sector average: -100.59%) and against ACOR's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 141.8%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Acorda Therapeutics, and consider following ACOR for alerts when major investors trade the stock.

Acorda Therapeutics is classified in the Healthcare sector. On ROE, it currently shows 141.8% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ACOR with unrelated industries.